GlassScriptPhysician profile
George A Nelson
NPI 1790075950
$10,515.81
in general payments reported to CMS, 2019-2025
39 companies · $2,456 in 2025
The $2,456 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $599 · 2021: $1,231 · 2022: $2,066 · 2023: $1,475 · 2024: $2,002 · 2025: $2,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,806 · Education: $99.64 · Gift: $27.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,805.77 |
| Education | $99.64 |
| Gift | $27.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,356.20 | 2019-2025 | |
| Janssen Biotech, INC. | $1,179.90 | 2020-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $968.42 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $638.66 | 2019-2025 | Entyvio, Gattex |
| Genzyme Corporation | $605.82 | 2022-2025 | |
| Pfizer INC. | $443.39 | 2019-2025 | |
| Gilead Sciences, INC. | $358.18 | 2021-2025 | Livdelzi |
| Ironwood Pharmaceuticals, INC | $346.15 | 2019-2024 | Linzess |
| Madrigal Pharmaceuticals | $310.61 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $300.08 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $277.44 | 2022-2025 | Ibsrela |
| Olympus America INC. | $262.52 | 2021-2023 | Evis Exera Lll Colonovideoscope |
| Celgene Corporation | $249.65 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $239.01 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $195.39 | 2024-2025 | Voquezna |
Show all 37 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.